NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Viking Therapeutics, Inc. VKTX
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-3.19
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-47.3%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 12-year series below
Revenue
Net income
Per share
USD -3.19
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-47.3%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-44.3%
Each USD of equity lost 47 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.11B
Shares outstanding, FY2025
Change, 5 years+56.8%
Change, 10 years—
The share count grew 57% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 715.7M
total assets, end of FY2025
Total assetsUSD 715.7M
EquityUSD 639.1M
CashUSD 165.8M
Current ratio9.33×
Equity funds 89% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.4
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.4
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−3.19
−1.01
−0.91
−0.90
−0.71
−0.54
−0.36
−0.38
−0.79
−0.90
−3.68
−5.23
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−47.3
−17.9
−34.8
−39.7
−24.6
−15.1
−9.0
−14.2
−191.4
−175.7
·
·
Shares out B
0.11
0.11
0.10
0.08
0.08
0.07
0.07
0.07
0.04
0.02
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
36 of 36
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed